{
    "clinical_study": {
        "@rank": "87222", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (standard stereotactic body radiation therapy (SBRT)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients undergo standard daily fractions of SBRT over 7-8.5 weeks"
            }, 
            {
                "arm_group_label": "Arm II (four fraction split-course SBRT)", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo 2 fractions of SBRT in weeks 1 and 4"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical trial studies stereotactic body radiation therapy in treating\n      patients with low- and intermediate-risk prostate cancer. Stereotactic body radiation\n      therapy may be able to send x-rays directly to the tumor and cause less damage to normal\n      tissue."
        }, 
        "brief_title": "Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Adenocarcinoma", 
            "Stage I Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate, in terms of late toxicity, the safety of stereotactic radiation therapy\n      using the proposed fractionation schedule.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate, in terms of acute toxicity, the safety of stereotactic radiation therapy\n      using the proposed fractionation schedule.\n\n      II. To determine stereotactic treatment efficacy through biochemical failure (Phoenix\n      criteria).\n\n      III. To determine the protocol completion rate.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients undergo standard daily fractions of stereotactic body radiation therapy\n      (SBRT) over 7-8.5 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have low or intermediate risk adenocarcinoma of the prostate as defined\n             by:\n\n               -  Low-risk disease - Histopathology score (Gleason sum): =<6, T-stage (per current\n                  AJCC staging criteria): T1c-T2a, and PSA: <10\n\n               -  Intermediate-risk disease as either:\n\n                    -  Histopathology score (Gleason sum) =< 6, T-stage (per current American\n                       Joint Committee on Cancer [AJCC] staging criteria): T1c-T2a, and\n                       prostate-specific antigen (PSA) > 10 but =< 20; or\n\n                    -  Histopathology score (Gleason sum) 7 with =< 50% of any cores positive,\n                       T-stage (per current AJCC staging criteria): T1c-T2a, and PSA < 10\n\n          -  Charlson index of comorbidity score =< 4\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients with history of inflammatory bowel disease, or who require steroid or\n             cytotoxic therapy for collagen vascular disease\n\n          -  Patients with a history of cancer other than skin cancer within 5 years of the\n             initiation of protocol treatment\n\n          -  Patients with a history of pelvic irradiation for any reason\n\n          -  Life expectancy < 10 years - Prior treatment with an anti-androgen, luteinizing\n             hormone-releasing hormone (LHRH) agonist, or a combination of the two\n\n          -  Prior radiation therapy, brachytherapy, or cryotherapy\n\n          -  Prior surgical procedure involving peri-rectal and peri-prostatic area"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737151", 
            "org_study_id": "MCC-14712", 
            "secondary_id": "NCI-2012-02545"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (standard stereotactic body radiation therapy (SBRT)", 
                "description": "Undergo SBRT", 
                "intervention_name": "stereotactic body radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "SBRT, stereotactic radiation therapy, stereotactic radiotherapy"
            }, 
            {
                "arm_group_label": "Arm II (four fraction split-course SBRT)", 
                "description": "four fraction split-course SBRT", 
                "intervention_name": "four fraction split-course SBRT", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tns3b@virginia.edu", 
                    "last_name": "Timothy N Showalter, MD", 
                    "phone": "434-243-1462"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia Medical Center"
                }, 
                "investigator": {
                    "last_name": "Timothy N Showalter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "manscher@mcvh-vcu.edu", 
                    "last_name": "Mitchell Anscher, MD", 
                    "phone": "804-828-7238"
                }, 
                "contact_backup": {
                    "email": "daholdfo@vcu.edu", 
                    "last_name": "Diane Holdford, RN", 
                    "phone": "804-828-0296"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Virginia Commonwealth University, Massey Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Mitchell Anscher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vicki.skinner@va.gov", 
                    "last_name": "Vicki Skinner, RN", 
                    "phone": "804-675-5646"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23249"
                    }, 
                    "name": "Hunter Holmes McGuire VA Medical Center"
                }, 
                "investigator": {
                    "last_name": "Michael Chang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of 4-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Intermediate Risk Adenocarcinoma of the Prostate", 
        "other_outcome": {
            "measure": "Acute toxicity greater than or equal to grade 2 as defined by the CTCAE version 4 criteria", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 5 years"
        }, 
        "overall_contact": {
            "email": "manscher@mcvh.vcu.edu", 
            "last_name": "Mitchell Anscher, MD", 
            "phone": "804-828-7238"
        }, 
        "overall_contact_backup": {
            "email": "daholdfo@vcu.edu", 
            "last_name": "Diane Holdford, RN", 
            "phone": "804-828-0296"
        }, 
        "overall_official": {
            "affiliation": "Virginia Commonwealth University", 
            "last_name": "Mitchell Anscher, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Will be tested using a continuity corrected chi-square test", 
            "measure": "Late toxicity greater than or equal to grade 2 as defined by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737151"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Biochemical failure as defined by the Phoenix definition", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}